Skip to main content
Erschienen in: European Journal of Nutrition 1/2022

27.06.2021 | Original Contribution

Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer

verfasst von: Rainer J. Klement, Detlef Meyer, Stefan Kanzler, Reinhart A. Sweeney

Erschienen in: European Journal of Nutrition | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Interest in ketogenic diets (KDs) as complementary nutritional treatments for cancer patients is rising, although some skepticism about their safety exists. We, therefore, studied the effects of KDs on quality of life and blood parameters in rectal cancer patients undergoing radio-chemotherapy.

Methods

EORTC-QLQ30 questionnaire scores and different metabolic and hormonal blood parameters were obtained prior to, in the middle of and at the end of radiotherapy within the KETOCOMP study (ClinicalTrials.gov Identifier: NCT02516501). A total of 18 patients consuming a KD were compared to 23 patients consuming their standard diet (SD). Baseline-end differences were measured using Wilcoxon tests, and repeated measures analysis was performed using linear mixed effects models.

Results

Eighty-nine percent of patients on the KD reported subjectively feeling good or very good, but roughly half of them rated the daily routine implementation as difficult. Only the SD group experienced significant declines in physical and role functioning, while the KD group improved in role (p = 0.045), emotional (p = 0.018) and social functioning (p = 0.009).Urinary frequency, buttock pain and fatigue significantly increased in the SD group, but to a much lesser extent in the KD group. Several biomarkers of metabolic health (gamma-glutamyl-transpeptidase, triglyceride-glucose index, HDL cholesterol/triglyceride ratio, and free T3) improved in the KD, but not the SD group.

Conclusions

Despite being perceived as difficult to implement by ≈50% of patients, KDs are feasible as complementary therapies alongside radio-chemotherapy and associated with subjective well-being. The hypothesis that they exert beneficial effects on quality of life and metabolic health in rectal cancer patients is supported by our data.

Trial registration

ClinicalTrials.gov identifier NCT02516501, registered Aug 6th 2015.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
This threshold was chosen based on the conversion between p values and minimum Bayes factors [52]. Bayes factors (or likelihood ratios in case of simple hypotheses) measure the strength of evidence between two competing hypotheses [70]. In exploratory analyses, a p value of 0.01 corresponds to a minimum Bayes factor of 1/6.5, providing moderate to strong evidence against the null hypothesis [52].
 
2
according to our definition of significance (p < 0.01).
 
Literatur
1.
Zurück zum Zitat Miller VJ, Villamena FA, Volek JS (2018) Nutritional ketosis and mitohormesis: potential implications for mitochondrial function and human health. J Nutr Metab 2018:5157645CrossRef Miller VJ, Villamena FA, Volek JS (2018) Nutritional ketosis and mitohormesis: potential implications for mitochondrial function and human health. J Nutr Metab 2018:5157645CrossRef
3.
Zurück zum Zitat Hao G-W, Chen Y-S, He D-M et al (2015) Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev 16:2061–2068CrossRef Hao G-W, Chen Y-S, He D-M et al (2015) Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev 16:2061–2068CrossRef
5.
Zurück zum Zitat Stafford P, Abdelwahab MG, Kim DY et al (2010) The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 7:74CrossRef Stafford P, Abdelwahab MG, Kim DY et al (2010) The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 7:74CrossRef
9.
Zurück zum Zitat Aminzadeh-Gohari S, Feichtinger RG, Vidali S, et al (2017) A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model. Oncotarget 8:64728–64744. https://doi.org/10.18632/oncotarget.20041 Aminzadeh-Gohari S, Feichtinger RG, Vidali S, et al (2017) A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model. Oncotarget 8:64728–64744. https://​doi.​org/​10.​18632/​oncotarget.​20041
13.
Zurück zum Zitat Schmidt M, Pfetzer N, Schwab M et al (2011) Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab (Lond) 8:54CrossRef Schmidt M, Pfetzer N, Schwab M et al (2011) Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab (Lond) 8:54CrossRef
22.
Zurück zum Zitat Lussier DM, Woolf EC, Johnson JL et al (2016) Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer 16:10CrossRef Lussier DM, Woolf EC, Johnson JL et al (2016) Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer 16:10CrossRef
29.
Zurück zum Zitat Fearon KC, Borland W, Preston T et al (1988) Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr 47:42–48CrossRef Fearon KC, Borland W, Preston T et al (1988) Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr 47:42–48CrossRef
33.
Zurück zum Zitat Klassen PN, Goldenberg BA, Lambert P et al (2020) Ketogenic and low-sugar diets for patients with cancer: perceptions and practices of medical oncologists in Canada. Support Care Cancer 28:5243–5249CrossRef Klassen PN, Goldenberg BA, Lambert P et al (2020) Ketogenic and low-sugar diets for patients with cancer: perceptions and practices of medical oncologists in Canada. Support Care Cancer 28:5243–5249CrossRef
35.
Zurück zum Zitat Klement RJ, Sweeney RA, Gross EC, Champ CE (2019) Problems associated with a highly artificial ketogenic diet: Letter to the Editor Re: van der Louw EJTM, Olieman JF, van den Bemt PMLA, et al. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety. Ther Adv Med Oncol 11:1758835919879268. https://doi.org/10.1177/1758835919879268CrossRefPubMedPubMedCentral Klement RJ, Sweeney RA, Gross EC, Champ CE (2019) Problems associated with a highly artificial ketogenic diet: Letter to the Editor Re: van der Louw EJTM, Olieman JF, van den Bemt PMLA, et al. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety. Ther Adv Med Oncol 11:1758835919879268. https://​doi.​org/​10.​1177/​1758835919879268​CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Bosy-Westphal A, Schautz B, Later W et al (2013) What makes a BIA equation unique? Validity of eight-electrode multifrequency BIA to estimate body composition in a healthy adult population. Eur J Clin Nutr 67:S14–S21CrossRef Bosy-Westphal A, Schautz B, Later W et al (2013) What makes a BIA equation unique? Validity of eight-electrode multifrequency BIA to estimate body composition in a healthy adult population. Eur J Clin Nutr 67:S14–S21CrossRef
48.
Zurück zum Zitat Kämmerer U, Schlatterer C, Knoll G (2012) Krebszellen lieben Zucker—Patienten brauchen Fett, 1st edn. Systemed Kämmerer U, Schlatterer C, Knoll G (2012) Krebszellen lieben Zucker—Patienten brauchen Fett, 1st edn. Systemed
50.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLC-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRef Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLC-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRef
51.
Zurück zum Zitat Fayers P, Aaronson N, Bjordal K et al (2001) The EORTC QOL-C30 scoring manual (3rd Edition). European Organisation for Research and Treatment of Cancer, Brussels Fayers P, Aaronson N, Bjordal K et al (2001) The EORTC QOL-C30 scoring manual (3rd Edition). European Organisation for Research and Treatment of Cancer, Brussels
52.
Zurück zum Zitat Held L, Ott M (2018) On p -values and Bayes factors. Annu Rev Stat Its Appl 5:393–419CrossRef Held L, Ott M (2018) On p -values and Bayes factors. Annu Rev Stat Its Appl 5:393–419CrossRef
70.
Zurück zum Zitat Bandyopadhyay PS, Brittan G Jr, Taper ML (2016) Belief, evidence, and uncertainty: problems of epistemic inference, 1st edn. Springer International Publishing, BaselCrossRef Bandyopadhyay PS, Brittan G Jr, Taper ML (2016) Belief, evidence, and uncertainty: problems of epistemic inference, 1st edn. Springer International Publishing, BaselCrossRef
Metadaten
Titel
Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer
verfasst von
Rainer J. Klement
Detlef Meyer
Stefan Kanzler
Reinhart A. Sweeney
Publikationsdatum
27.06.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nutrition / Ausgabe 1/2022
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-021-02615-y

Weitere Artikel der Ausgabe 1/2022

European Journal of Nutrition 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.